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ARTICLE
Genomic epidemiology of syphilis reveals
independent emergence of macrolide resistance
across multiple circulating lineages
Mathew A. Beale 1, Michael Marks 2,3, Sharon K. Sahi4, Lauren C. Tantalo4, Achyuta V. Nori5,
Patrick French6, Sheila A. Lukehart7, Christina M. Marra4 & Nicholas R. Thomson1,8
Syphilis is a sexually transmitted infection caused by Treponema pallidum subspecies pallidum
and may lead to severe complications. Recent years have seen striking increases in syphilis in
many countries. Previous analyses have suggested one lineage of syphilis, SS14, may have
expanded recently, indicating emergence of a single pandemic azithromycin-resistant cluster.
Here we use direct sequencing of T. pallidum combined with phylogenomic analyses to show
that both SS14- and Nichols-lineages are simultaneously circulating in clinically relevant
populations in multiple countries. We correlate the appearance of genotypic macrolide
resistance with multiple independently evolved SS14 sub-lineages and show that genotypi-
cally resistant and sensitive sub-lineages are spreading contemporaneously. These ﬁndings
inform our understanding of the current syphilis epidemic by demonstrating how macrolide
resistance evolves in Treponema subspecies and provide a warning on broader issues of
antimicrobial resistance.
https://doi.org/10.1038/s41467-019-11216-7 OPEN
1 Parasites and Microbes, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK. 2 Clinical Research Department, Faculty of
Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK. 3 Hospital for Tropical Diseases, London, UK. 4Department of
Neurology, University of Washington, Seattle, WA 98195, USA. 5 Guy’s & St Thomas’ NHS Foundation Trust, London, UK. 6 The Mortimer Market Centre
CNWL, Camden Provider Services, London, UK. 7 Departments of Medicine and Global Health, University of Washington, Seattle, WA 98195, USA.
8Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Correspondence and requests for materials should be addressed to M.A.B. (email: mathew.beale@sanger.ac.uk) or to N.R.T. (email: nrt@sanger.ac.uk)
NATURE COMMUNICATIONS |         (2019) 10:3255 | https://doi.org/10.1038/s41467-019-11216-7 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Syphilis is a centuries-old, predominantly sexually trans-mitted infection (STI) caused by the bacterium Treponemapallidum subspecies pallidum (TPA). If untreated, syphilis
causes a multi-system disease that can progress to severe cardi-
ovascular and neurological involvement, which can be potentially
fatal. Syphilis caused a pandemic wave that swept across
Renaissance Europe over 500 years ago, and remained a problem
until the introduction of antibiotics in the post-World War II
era1. Despite effective treatment with benzathine benzylpenicillin
G (BPG), syphilis transmission levels ﬂuctuated but persisted
throughout the 20th century, until the AIDS crisis of the 1980s
and 1990s, where changes in sexual behaviour (and possibly
AIDS-related mortality), led to an overall decline in incidence in
many western countries and populations2,3.
Recent years have seen a sharp increase in syphilis cases in
many high-income countries, predominantly within sexual net-
works of men who have sex with men (MSM)4,5. In the United
Kingdom there was a 20% increase in reported new diagnoses
between 2016 and 2017, and a 148% increase since 20086. Similar
trends have been reported in other countries4,7. The reasons for
this increase are complex and multifactorial, incorporating
changing behavioural patterns mediated by cultural, societal and
technological changes in our modern world8, resulting in a per-
fect epidemiological storm. It is also possible that there are bac-
terial changes either driving the current rise in syphilis incidence,
or occurring as a consequence of this increase. However, current
knowledge of TPA is limited, largely because the bacterium was,
until recently, intransigent to in vitro culture9. Most current
understanding of TPA biology therefore comes from related
species or from TPA cultured in the in vivo rabbit testicular
model10. Genomic analysis has also been limited due to low levels
of TPA pathogen load in patients and difﬁculty in readily iso-
lating new strains. Sequencing must be performed directly on
clinical specimens or after passage through rabbits, leading to
substantial bottlenecks in genomic data generation. Recent
advances have enabled target enrichment of pathogen reads
directly from clinical or cultured specimens11,12, and this was
recently employed separately by different groups, including our
own, to sequence TPA and other T. pallidum subspecies directly
from patient samples13–15.
The availability of increasing numbers of genomic sequences
enabled the ﬁrst description of the global TPA population structure
using 31 near genome-length TPA sequences, along with a small
number derived from closely related species14. The authors
described two lineages within TPA; a Nichols-lineage found almost
exclusively in North American sequences exhibiting substantial
nucleotide diversity, and a geographically widespread but genetically
homogeneous SS14-lineage, conﬁrming previous analyses using
multi-locus sequence typing16. Of these two lineages, they found
that 68% of tested TPA genomes belonged to the SS14-lineage, and
further analysis using a larger dataset of 1354 single-locus molecular
types (comprising 623 samples from South East Asia, 241 from the
United States, 392 from Europe and a small number of other
locations) also supported this view (94% SS14-lineage).
Although penicillin resistance has never been reported in
syphilis, increasing levels of genotypic resistance, and clinical
treatment failure, to macrolides such as azithromycin have been
reported17,18, conferred by either one of two single nucleotide
polymorphisms (SNPs) in the 23S ribosomal sequence (A2058G
and A2059G). Previous molecular typing studies indicated that
differential patterns of macrolide resistance correlate with geo-
graphical location17–19 and molecular type18,20–22, and Arora
et al. reported that 90% of whole-genome sequenced SS14-lineage
genomes and 25% of Nichols-lineage genomes contained SNPs
conferring macrolide resistance; furthermore, it has been sug-
gested that SS14-lineage may represent a single pandemic
azithromycin-resistant cluster14 perhaps related to azithromycin
selective pressure14,16.
In this study, we use direct whole-genome sequencing on 73
TPA samples from the US and Europe, and combine these data
with 49 publicly available genomes. We test the hypothesis that,
as with other pathogens23, expansion of the SS14-lineage might
have been driven by selection of macrolide resistance. We use
phylogenetic analysis to delineate sub-lineages within the both the
SS14- and Nichols-lineages, providing an evolutionary framework
for the emergence of macrolide resistance in treponemas, and
showing striking patterns of the emergence and ﬁxation of
macrolide resistance SNPs that indicate independent evolution
and proliferation of resistance alleles. These ﬁndings have
implications for the potential of the WHO Yaws eradication
campaign to drive further development of macrolide resistance in
both TPA and in the closely related Treponema pallidum sub-
species pertenue (TPP)24,25.
Results
Clinical genomes are mostly but not exclusively SS14-lineage.
We sequenced eight genomes directly from clinical swabs col-
lected in 2016 from patients in the United Kingdom and 60
isolate genomes from low rabbit passage samples (no more than
two passages from the original patient sample; henceforth refer-
red to as recently clinically derived) originally collected from
patients between 2001 and 2011 in the United States. We also
resequenced three clonally derived laboratory strains from the
United States that have been previously sequenced (Nichols
Houston E, Nichols Houston J, Nichols Houston O) but remain
unpublished, and two strains for which the sequencing reads were
not publicly available (Chicago26, Seattle 81-427). We combined
our data with 49 high-quality genomes published
previously13,14,28–33, 41 of which were recently derived from
clinical patients, yielding a dataset of 122 genomes (109 with
limited passage from clinical patients). Combined, our sample set
included 72 genomes from the United States (predominantly
Seattle), 8 from the United Kingdom (exclusively London), 9
from China (predominantly Shanghai), 23 from Portugal
(exclusively Lisbon), and a small number from other countries, all
collected between 1912 and 2016 (Supplementary Data 1).
After removal of recombinant and repetitive sites (both by
selective mapping and screening—see Methods and Supplemen-
tary Data 2), we performed phylogenomic analyses, using
maximum likelihood and Bayesian methods to deﬁne lineages.
In agreement with previous studies14, we show the presence of
two dominant lineages in our dataset (previously denoted SS14
and Nichols; Fig. 1) that are separated by > 70 non-recombining
single nucleotide polymorphisms (SNPs). Of the 122 total
samples included in this study, 105 (86%) belonged to the
SS14-lineage, whilst of the 109 recently clinically derived samples
included, 103 (94%) were from SS14-lineage. In contrast, only six
Nichols-lineage samples were recently clinically derived, and
most (11/17) Nichols-lineage genomes examined were historically
passaged isolates, including those derived from the original
Nichols strain isolated in 1912 and disseminated to different
North American laboratories; some Nichols-lineage genomes
represent clones of the parent strain derived in vivo. However,
although we observed a strong bias towards clinically derived
SS14-lineage samples in this dataset, not all recent clinical strains
were of the SS14-lineage; six recent clinical samples belonged to
the Nichols-lineage, three (of eight sequenced) clinical samples
from the United Kingdom in 2016, one collected in the
Netherlands in 2013, and two from the United States in 2004,
indicating that transmission of this lineage is ongoing and
potentially more widespread than previously thought.
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Bayesian phylogenetic reconstruction was used to date the time
to most recent common ancestor (TMRCA) for the different TPA
lineages. However, temporal analysis of heavily passaged
laboratory strains (such as those derived from the original
Nichols isolate) is problematic because the true mutational age
may be unknown, meaning coalescent date is difﬁcult to infer; we
therefore removed extensively passaged strains or strains with no
record of their passage history from this particular part of the
analysis. This included the removal of the Nichols and SS14
reference strains, as well as the Mexico A strain that delineated
the SS14Ω lineage described previously14. Root-to-tip regression
analysis of the remaining 109 recently clinically derived genomes
indicated that TPA possesses a clock-like signal (Supplementary
Figure 1), and we performed Bayesian phylogenetic reconstruc-
tion and tip date analysis using BEAST34 under a Strict Constant
model, inferring a median molecular clock rate of 1.78 × 10−7
(95% Highest Posterior Density (HPD) 1.15 × 10−7 – 2.44 × 10–7),
or 0.20 sites/genome/year (meaning we would expect TPA
genomes on average to accumulate one ﬁxed SNP every 5 years).
We inferred a temporal timeline for the tree, and our analysis
broadly supported previous estimates14 dating the separation of
Nichols- and SS14- lineages between the 17th and 18th Centuries
(median date 1662, 95% HPD 1517–1791; Fig. 2a).
SS14-lineage shows a polyphyletic structure. Within the SS14-
lineage, the high number of full-length sequences enabled ﬁne-
scale description of phylogenetic sub-structure. In particular, we
show partitioning of the SS14Ω centroid cluster previously
deﬁned14 into two lineages; one composed of European and
North American derived samples (SS14Ω-A), and another of
Chinese and North American derived samples (SS14Ω-B) (Fig. 1).
While the American and European samples belonging to the
former SS14Ω-A lineage are geospatially admixed, those of the
latter SS14Ω-B lineage can be further separated between Chinese
and North American samples. These partitions were well sup-
ported in our maximum likelihood (Fig. 1) and Bayesian phylo-
genies (Fig. 2a), as indicated by black node points. We used the
rPinecone package35 to formally classify these sub-lineages based
on a deﬁned root-to-tip SNP distance, identifying eight sub-
lineages (one of which we further subdivided into sub-lineages 1A
and 1B to aid analysis based on temporal and geospatial diver-
gence) within SS14-lineage that correlated well with the popula-
tion structure described by the phylogeny (Fig. 2a, Supplementary
Figure 2). Importantly, while some nodes close to the tips in our
phylogeny are unsupported due to small numbers of differ-
entiating SNPs, all sub-lineages deﬁned by rPinecone are sup-
ported by > 91% posterior support at the key nodes in our
Bayesian phylogeny (Fig. 2a). We considered the possibility of
geographical bias in our data, and whilst four sub-lineages are
composed entirely of samples from Seattle (sub-lineages 1A, 3, 4)
or China (sub-lineage 1B), four others (sub-lineages 2, 5, 7, 8) are
geospatially admixed, sharing samples from both the United
States and Europe, with the last (sub-lineage 6) composed of
samples from two European countries, Portugal and the Neth-
erlands (Supplementary Figures 2 and 3, Supplementary Data 1).
Macrolide resistance has evolved independently within SS14.
The molecular basis for macrolide resistance has been well
documented in T. pallidum, and is mediated by point mutations
in the 23S ribosomal RNA gene at nucleotide positions 2058 and
205936–38. The A2058G variant was ﬁrst identiﬁed in T. pallidum
Street Strain-14 (the prototype sample for the SS14-lineage),
isolated as long ago as 197736, yet resistance has not previously
been analysed in context with a detailed whole-genome phylo-
geny. We initially used ARIBA39 to perform localised assembly
and variant calling of treponema-speciﬁc 23S ribosomal sequen-
ces from all genomes, and these data were used to infer the
presence of both A2058G and A2059G 23S variants that confer
macrolide resistance36. T. pallidum possesses two copies of the
23S ribosomal RNA gene, yet previous analyses of T. pallidum
have not identiﬁed heterozygosity between these two copies
(although heterozygosity was described for the distantly related T.
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Fig. 1 Maximum likelihood phylogeny of 122 high-quality T. pallidum
subspecies pallidum genomes, showing lineage and country of origin. Tree
includes sequences from recently clinically derived samples and those with
more extensive laboratory passage. Ultra-Fast bootstrap values >= 95%
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denticola40)—where resistance alleles have been sequenced, they
are homozygous between 23S copies, and it has been suggested a
gene conversion uniﬁcation mechanism may exist to facilitate
this18. In our initial analysis of the 122 genomes, 83 showed
evidence of genotypic resistance to macrolides, with 76 genomes
showing > 95% read support for either the A2058G or A2059G
variant. Since it is not possible to discriminate between short
reads originating from either copy of 23S because they are perfect
repeats, this suggests that both copies carry the same resistance
mutation. Seven clinically derived genomes (one UK sample from
this study, six described by Pinto and colleagues13) showed a
mixed 23S allelic proﬁle (replicating the result of a previous
analysis for three of six samples13). All of these samples had >
179x read coverage for those sites, with only a fraction of reads
(26–94%) possessing a resistance allele. In these cases it was not
possible to clearly distinguish between a mixture of homozygous
positive and negative bacteria in the same patient (either due to
within-host evolution or coinfection with multiple strains) or
heterozygous sequences from a single bacterium (different 23S
rRNA alleles at each copy; heterozygosity in phase) (Fig. 2a).
In the course of our analysis, we determined that many of the
samples with mixed alleles from publicly available datasets also
contained contaminating reads from other species despite the use
of sequence capture based enrichment approaches; many of these
contaminating reads corresponded to genomic regions with
substantial homology to other bacterial species. In particular, the
23S is broadly conserved across bacteria, with the region
immediately preceding the 2058/2059 locus sharing 100% k-
mer identity with over 326,000 other bacterial datasets, and this
can lead to problems for both assembly and mapping approaches
to SNP calling in this region41. For example, Kraken42 analysis
showed that the read set for sample SW6 (accession
SRR3268732), which in our initial analysis using ARIBA appeared
to be negative for the A2058G SNP, actually contained 29%
Streptococcus galactiae reads, most of which clustered in the 23S,
where read depth reached over 70,000x for the region
immediately preceding the 2058/2059 locus. This can lead to
failures of both assembly and mapping approaches, since reads
homologous to this region would have anomalous mate pairs.
Careful manual examination of the reads showed that the SNP
was indeed present, and we used stringent competitive mapping
against comparable genomic regions from multiple species as
described by Hadﬁeld and colleagues43, whereby only reads with
appropriately mapping mates are considered, to deconvolute
these mixtures throughout the dataset. Using this approach, we
determined that SW6 was indeed genotypically resistant at
A2058G, as well as demonstrating that the majority of mixed
alleles detected were in fact the result of contaminating reads, and
that the Treponema-derived reads were positive for A2058G.
Where competitive mapping could not conclusively establish the
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genotype of alleles, they are described as “uncertain” throughout
this manuscript.
Within the 122 genomes included in this study, we observed
that 71% (74/105) of SS14-lineage samples and 35% (6/17) of
Nichols-lineage samples were homozygous for either A2058G or
the A2059G 23S rRNA allele. In the SS14-lineage, samples
possessed either the A2058G (n= 63) or the A2059G (n= 11)
variant. In the Nichols-lineage, six possessed a resistance allele, of
which all showed the A2058G variant, and all were from recent
clinically derived samples.
To explore the emergence of macrolide resistance, we
correlated the taxa in our time-scaled phylogeny with the
presence of resistance alleles (Fig. 2a). We observed a strong
correlation between our well supported sub-lineages and
genotypic macrolide resistance or sensitivity, such that resistance
appears to have evolved on multiple occasions in a stepwise
manner (Fig. 2a). For example, Fig. 2b shows how the wild-type
ancestor of sub-lineage 1B sequences evolved the A2058G
between the late 1980s and late 1990s, contrasting with sub-
lineage 1A sequences which did not gain A2058G, but
subsequently and independently evolved the A2059G variant.
More broadly in the phylogeny, we observe that similar
independent 23S rRNA mutations have occurred on at least six
occasions (Fig. 2a), with separate sub-lineages characterised by
either predominantly macrolide resistant or sensitive genotypes;
six of the nine sub-lineages were predominantly resistant to
macrolides, with three sub-lineages being predominantly sensi-
tive. Several of the macrolide sensitive sub-lineages (in particular
sub-lineage 3) contained similar numbers of samples as many of
the resistant sub-lineages (Fig. 3), suggesting ongoing selection
for macrolide resistance has not inﬂuenced the expansion of these
sub-lineages.
To examine sub-lineage expansion in greater detail, we
extracted sampling dates according to sub-lineage, and correlated
these data with the predicted time to most recent common
ancestor (TMRCA) (Fig. 3). Whilst all clinical sequences included
in this analysis were sampled after 2000, our analysis indicates
that the origins of most of the sub-lineages predated this time and
likely arose between the late 1980s and early 2000s (Fig. 3).
Regarding whole sub-lineage associated resistance, we also
observed more recent sporadic appearance of resistance muta-
tions, with two separate A2058G variants detected in sub-lineage
3 (an otherwise macrolide sensitive sub-lineage) (Fig. 2).
Penicillin binding proteins show homoplasic changes. Previous
analysis of Treponemal genomes have shown amino acid changes
in penicillin binding proteins13,28, but large scale analysis of
penicillin gene variants has not previously been performed on a
global dataset. We selected three penicillin binding protein
genes44,45 (pbp1, pbp2, mrcA) and a putative β-lactamase46
(Tp47), and used competitive mapping to individual gene
sequences to screen for novel variants across our full clinical
dataset of 109 sequences, identifying 13 non-synonymous SNPs
(Supplementary Figure 4). Two variants (pbp1 P564L; Tp47
S394R) were almost universally conserved in clinical SS14-lineage
sequences, whilst three more (mrcA I487L; mrcA M625V; mrcA
G708S) showed strong association with SS14 sub-lineages. As no
phenotypic or clinical evidence exists for penicillin resistance or
treatment failure in Treponemes, we considered such widely
prevalent SNPs unlikely to be of clinical relevance or mediate a
resistant phenotype.
Sun and colleagues28 identiﬁed variants in pbp2 (pbp2 I415F/
I415M) and mrcA (mrcA A506V) in eight genomes from China,
and whilst we conﬁrmed the presence of the pbp2 variants, we did
not ﬁnd them in samples from other countries. However, in
addition to the mrcA A506V variant described by Sun et al., we
also identiﬁed a SNP affecting the same amino acid position
(mrcA A506T), both in the recently clinically derived Nichols-
lineage genomes as well as in recently clinically derived SS14 sub-
lineage 1A (comprising samples from the United States). As with
macrolide resistance, independent evolution of homoplasic
variants affecting the same amino acid are suggestive of selection,
and we used SIFT47 to infer the likely functional impact of amino
acid changes at mrcA A506 and pbp2 I415. None of the four
variants detected showed a signiﬁcant result (no SIFT scores were
below the threshold for functional effect of 0.05), leaving the
clinical relevance of these SNPs unclear.
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Discussion
Compiling the largest Treponema pallidum subspecies pallidum
sequence collection to date, we show that the majority of the
contemporary samples sequenced here were from the SS14-line-
age, consistent with other reports14. However, three of eight
recent UK genomes (38%) belonged to the Nichols-lineage,
showing that these two lineages are still circulating concurrently,
and that the prevalence of Nichols-lineage strains may vary by
sampling population. Moreover, linking the phylogenetic and
geospatial data of our samples shows that a number of SS14 sub-
lineages (2, 5, 7, 8) are comprised of both European and North
American samples (Supplementary Figure 2, Supplementary
Figure 3), suggesting that we have captured key lineages circu-
lating in these regions and that our data are not overly biased
from localised sampling. Notwithstanding the above, further
studies will be needed to more accurately characterise the geno-
mic diversity and prevalence of lineages within different popu-
lations on a global scale.
We were able to reconstruct a time-scaled phylogeny using
only recently clinically derived samples, and the increase in
whole-genome sequence numbers combined with the removal of
heavily passaged samples contrasts with previous approaches14,28.
Arora et al. reported a mean evolutionary rate of 6.6 × 10−7
substitutions/site/year for T. pallidum14, comparable with rapidly
dividing, free-living bacterial pathogens with environmental life
cycles such as Vibrio cholerae (6.1 × 10–7)48 and Shigella sonnei
(6.0 × 10–7). However, T. pallidum is a slow growing host-
restricted pathogen with substantial periods of latency, and as
such we would expect a molecular clock rate more similar to
other slow growing organisms such as Chlamydia trachomatis
(2.15 × 10−7)43 or Mycobacterium tuberculosis (1 × 10−7)49. Our
inferred rate for TPA (1.78 × 10–7) is consistent with this
expectation, as well as with other observations that suggest T.
pallidum has a low evolutionary rate50.
Within the SS14-lineage, we deﬁned nine well supported sub-
lineages that all diverged from their most recent common
ancestors prior to 2006, with the earliest (sub-lineage 3) poten-
tially emerging during the 1980s. We observed clear associations
between these nine sub-lineages and the presence of macrolide
resistance conferring SNPs, with each sub-lineage dominated by
either macrolide resistant (six sub-lineages) or macrolide sensitive
(three sub-lineages) samples. Such observations, previously
documented to a limited extent within a single country13 but now
extended to a broader sample, are not consistent with a
hypothesis of an ancestrally resistant SS14-lineage driven to high
frequency in the population due to a ﬁtness advantage conferred
by macrolide resistance, where we would expect to see expansion
of a single resistant lineage. Rather, we see evidence of multiple
sub-lineages independently evolving macrolide resistance alleles,
as a likely consequence of intermittent selective pressure from
macrolide treatment, consistent with molecular typing data from
Seattle20. Phylogenetic reconstruction shows de novo evolution of
macrolide resistance in syphilis is not a rare event, and further-
more, when resistance evolves in a lineage, it persists in descen-
dants, resulting in transmission from person to person. That the
variants appear stable within lineages, with no examples in the
phylogeny that might represent reversion to a wild-type state,
suggests that either there is no strong ﬁtness cost associated with
possessing these macrolide resistance mutations or that novel
compensatory variants co-evolve to mitigate any ﬁtness cost,
enabling variant stability; further sampling would be necessary in
the future to address this.
Although our data strongly suggest that global expansion of the
SS14-lineage is not contingent on macrolide resistance, the global
increases seen in macrolide resistant syphilis18, as well as the
number of resistant lineages emerging in our data, are a cause for
concern. Macrolides, such as azithromycin, are not considered
appropriate treatment for syphilis, with WHO and US guidelines
recommending treatment with BPG51,52, with doxycycline
recommended as a secondary treatment option. In contrast,
WHO now recommends azithromycin rather than BPG as the
treatment of choice for mass drug administration in the eradi-
cation of yaws24, caused by the closely related T. pallidum sub-
species pertenue. Macrolide resistance has recently been described
in yaws25 and our data suggest that further independent evolution
of azithromycin resistance is highly likely, which would have
signiﬁcant implications for yaws eradication efforts. Worryingly,
applying azithromycin-based mass drug administration to
populations infected with both TPP and TPA could promote
resistance in both species.
Several factors are likely to have driven the repeated evolution
and subsequent expansion of macrolide resistant lineages of TPA.
Use of azithromycin, or other macrolides, for other indications is
likely to have played a signiﬁcant role53. Azithromycin entered
global markets between 1988 and 1991 (marketed by Pﬁzer as
Zithromax), and became one of the most widely used antibiotics
in the United States for a wide variety of indications54, including
the treatment of respiratory tract infections and for the treatment
of other sexually transmitted infections. In many cases, the dose
used for treatment of these indications is lower than the recom-
mended dose for the treatment of syphilis. Azithromycin and
clarithromycin were also widely used prophylactically amongst
individuals living with HIV prior to the widespread availability of
combined anti-retroviral therapy. Off-target macrolide exposure
is of particular concern because azithromycin has a long half-
life55 and may persist at sub-therapeutic concentrations in
patients. Widespread use of macrolides for this broad range of
indications might therefore have contributed to sub-therapeutic
exposure of patients with incubating or early syphilis and ulti-
mately selection of resistance53.
The recent increase in incidence of syphilis in high-income
countries likely reﬂects changes in sexual behaviour8. The fact
that we observe the expansion of both genotypically resistant and
sensitive lineages highlights particular treatment issues. There
have been signiﬁcant global shortages of BPG56 in low, middle,
and high-income nations, including the United States, with the
global supply of BPG dependent on just three manufacturers of
the active ingredient56. Pharmaceutical production of sterile,
injectable β-lactam-derived antimicrobials such as BPG is costly,
yet as an older off-patent medication with declining demand in
the face of growing antimicrobial resistance (AMR) in other
organisms, the ﬁnancial rewards for production are low56. This
may be compounded by a misperception that BPG is an outdated
drug that could be replaced by newer, more effective drugs56. In
circumstances where azithromycin is used instead of doxycycline,
a shortage of BPG leads inevitably to inadequate treatment of
early infectious syphilis and contributes to ongoing, unchecked
transmission. In China for example, studies have reported that
despite high rates of macrolide resistance19, clinicians have
inappropriately been resorting to macrolide treatment due to
ongoing BPG shortages57. Thus although a well-established,
highly effective treatment for syphilis (BPG) has been available
since the mid-1950s, shortages in the present era contribute to
suboptimal treatment strategies and continued use of drugs with a
known resistance problem.
Phenotypic or clinical penicillin resistance has never been
observed in syphilis in more than 60 years of clinical use. In
our analysis, we detected a number of variants affecting
penicillin binding proteins, although given that penicillin
remains an effective treatment, many were so widely dis-
tributed throughout the phylogeny as to be implausible for
causing resistance.
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The epidemic of syphilis and the widespread problems of
azithromycin resistance and BPG shortage require a multi-faceted
response. This includes new strategies for treatment and reduc-
tion of transmission, ﬁnding ways to improve the security of the
BPG supply chain, and strengthening molecular surveillance for
antimicrobial resistance in T. pallidum58. Many authors have
discussed the importance of rethinking the economics of anti-
microbial development pipelines to ensure we are still able to
treat infections23,59. In syphilis, we must rethink how we can
protect the continued production of existing highly efﬁcacious
penicillins in the face of increasing antimicrobial resistance ren-
dering them ineffective for other organisms, especially in the light
of the recent increases in syphilis incidence in Europe, North
America, and Asia.
Methods
Samples. UK samples consisted of residual DNA, extracted from clinical swabs
using a QIAsymphony (Qiagen) from routine diagnostic samples obtained from
patients presenting with clinical evidence of syphilis at the Mortimer Market
Centre, London. Use of the UK samples was approved by the NHS Research Ethics
Committee (IRAS Project ID 195816). US samples from Seattle were collected from
individuals enrolled in a study of cerebrospinal ﬂuid abnormalities in patients with
syphilis (a mixture of 21 patients with evidence of CSF infection and 38 patients
without), with ethical approval at the University of Washington (UW IRB #
STUDY00003216). All relevant ethical regulations for work with human partici-
pants were followed, and informed consent was obtained for sampling and
research.
For US samples, 2.4–3.0ml participant blood or cerebrospinal ﬂuid was inoculated
intratesticularly into male New Zealand white rabbits (~3 kg) testes under sedation.
The rabbits were housed at 18–20 °C and fed antibiotic-free food. Each animal was
inspected at regular intervals for signs of orchitis (testicular swelling and hardness),
which occurs variably between 10 and 50 days depending on the strain. When
infection was suspected (conﬁrmed by positive darkﬁeld examination of testicular
aspirate or seroconversion), rabbits were euthanised, the popliteal lymph nodes and
testes removed, then minced and resuspended (50% normal rabbit serum, 50% saline)
and inoculated into a naive rabbit within 30–60min of collection. T. pallidum
suspensions collected after the second round of passage were used for DNA extraction
and sequencing. This well-established passage method has been described elsewhere
in detail; for speciﬁc protocols see Lukehart and Marra60. Historical strains were
propagated in rabbits and harvested from infected testes. Animal care was provided in
full accordance with established guidelines, and experimental procedures were
conducted under protocols approved in advance by the University of Washington
Institutional Animal Care and Use Committee.
T. pallidum suspensions from rabbits were treated using a lysis buffer (10mM
Tris pH 8.0, 0.1M EDTA pH 8.0, 0.5% SDS), freeze-thaw, and extraction using
QIAamp Mini kit (Qiagen) according to the manufacturer’s instructions; in select
cases the proteinase K incubation was extended overnight to improve DNA yield. In
some cases, samples had been used for previous molecular tests, and in these cases
residual DNA extracts were used for sequencing. Treponemal DNA was quantiﬁed
using a qPCR targeting the Tp47 (TPANIC_0574) gene that is conserved across all
known members of the T. pallidum cluster, and compared with a standard curve
derived from a plasmid containing the PCR amplicon. Samples with a concentration
> 2000 genome copies/μl were selected for sequencing; borderline samples with high
volume and a pathogen load over 500 genome copies/μl were concentrated using a
vacuum centrifuge. Samples were arranged in groups of 20 according to similar
(within 2CT) treponemal load, with high concentration outlier samples diluted as
necessary. We added 4 μl pooled commercial human gDNA (Promega) to all
samples to ensure total gDNA> 1 μg/35 μl, sufﬁcient for library prep.
Sequencing. Genomic DNA was sheared to 100–400 bp (average size distribution
~ 150 bp) by ultrasonication (LE220, Covaris Inc), followed by library preparation
(NEBNext Ultra II DNA Library prep Kit, New England Biolabs), adaptor ligation
and index barcoding (Sanger 168 tag set). Index tagged samples were ampliﬁed (six
cycles of PCR, KAPA HiFi kit, KAPA Biosystems), quantiﬁed (Accuclear dsDNA
Quantitation Solution, Biotium), then pooled in the preassigned groups of 20 to
generate equimolar total DNA pools. Five hundred nanograms of pooled material
was then hybridised using 120-mer RNA baits (SureSelect Target enrichment
system, Agilent Technologies) designed against published RefSeq examples of T.
pallidum and T. paraluiscuniculi (Bait design ELID ID 0616571)15. Libraries were
subjected to 125 bp paired-end sequencing on Illumina HiSeq 2500 with version 4
chemistry according to established protocols. This sequencing method has been
previously described15, and differs from that of others13,14, in that samples are
barcoded and pooled before enrichment thus enabling multiplexing of hybridisa-
tion reactions. Raw sequencing reads were deposited at the European Nucleotide
Archive (ENA) under project PRJEB20795; all accessions used in this project are
listed in Supplementary Data 1.
Sequence analysis and phylogenetics. Treponemal sequencing reads were pre-
ﬁltered using a Kraken42 v0.10.6 database containing all bacterial and archaeal
nucleotide sequences in RefSeq, plus mouse and human, to identify and extract
those reads with homology to Treponema species, followed by adaptor trimming
using Trimmomatic61 v0.33. To reduce bias due to variable read depth, as well as
make analysis computationally tractable, for samples with high read counts we
used seqtk v1.0 (available at https://github.com/lh3/seqtk) to randomly down-
sample the binned and trimmed reads to 2,500,000 unique treponemal read pairs.
For publicly available genomes, raw sequencing reads were downloaded from SRA
and subjected to the same binning and down-sampling pipeline. For eight public
genomes (see Supplementary Data 1), raw sequencing reads were not available; for
these we simulated 125 bp PE perfect reads from the RefSeq closed genomes using
Fastaq (available at https://github.com/sanger-pathogens/Fastaq).
For phylogenetic analysis, we used a reference mapping approach with a custom
version of the SS14 v2 reference sequence (NC_021508.1) from which we ﬁrst
masked 14 highly repetitive or recombinogenic genes (12 repetitive Tpr genes A-L,
arp and TPANIC_0470) using bedtools62 v2.17.0 maskfasta. We mapped
preﬁltered sequencing reads to the reference using BWA mem63 v0.7.17 (MapQ ≥
20), followed by indel realignment using GATK64 v3.4-46 IndelRealigner,
deduplication with Picard MarkDuplicates v1.127 (available at http://
broadinstitute.github.io/picard/), and variant calling and consensus
pseudosequence generation using samtools v1.265 and bcftools v1.2, requiring a
minimum of three supporting reads per strand and eight in total to call a variant,
and a variant frequency/mapping quality cut-off of 0.8; sites not meeting these
criteria were masked to ‘N’ in the pseudosequence. Importantly, reads mapping to
multiple positions were marked and excluded from SNP calling, meaning repeated
regions such as the duplicated 23S genes was not included in the multiple sequence
alignment used to derive the phylogenies.
Multiple sequence alignments were screened for evidence of recombination
using Gubbins66, generating recombination-masked full-genome length and SNP-
only alignments. Maximum likelihood phylogenies were calculated on SNP-only
alignments using IQ-Tree v1.6.367, correcting for missing constant sites using the
built-in ascertainment bias correction68, allowing the built-in model testing69 to
determine a K3P (three substitution types model and equal base frequencies)
substitution model70 with a FreeRate model of heterogeneity71 assuming three
categories, and performing 1000 UltraFast Bootstraps72.
To determine SS14 sub-lineages, we recalculated a maximum likelihood tree as
described above for SS14-clade sequences only (using the Mexico A strain,
NC_018722.1 as outgroup), before performing a joint ancestral reconstruction73 of
SNPs on the tree branches using pyjar (available at https://github.com/simonrharris/
pyjar). We then used the rPinecone package35 (available at https://github.com/
alexwailan/rpinecone), which applies a root-to-tip approach to deﬁning clusters
based on SNP distance relative to ancestral nodes. We used a cluster threshold of 10
SNPs, which proved optimal for describing the underlying phylogenetic structure of
the tree, and yielded eight sub-lineages. Within sub-lineage 1, we found that
pinecone clusters did not accurately represent the phylogeny, despite a clear
phylogenetic separation, with one group of sequences from China associated with
the A2058G allele, and the other group from the United States associated with the
A2059G allele. We further manually clustered these sequences according to their
shared ancestral nodes, naming them sub-lineages 1 A and 1B.
We evaluated our maximum likelihood phylogeny for evidence of temporal
signal using TempEst74 v1.5, and this showed a correlation of 0.40 and R2 of 0.16
for the whole tree (Supplementary Figure 1), whilst the SS14-lineage -only
alignment showed a correlation of 0.66 and R2 of 0.44; this indicated that there was
sufﬁcient evidence for temporal signal and we proceeded to BEAST analysis.
BEAST34 v1.8.2 was initially run on a recombination-masked SNP-only alignment
containing 276 variable sites, applying a correction for invariant sites using the
constantPatterns argument, in triplicate using an Uncorrelated Relaxed Clock
model, assuming constant population size, lognormal population distribution, GTR
substitution model, diffuse gamma distribution prior (shape 0.001, scale 1000),
with a burnin of 10 million cycles followed by 100 million MCMC cycles. All
MCMC chains converged, and on inspection of the marginal distribution of ucld.
stdev we could not reject a Strict Clock. We therefore repeated the analysis using a
Strict Clock model, using the same models and priors and assuming a starting
molecular clock rate of 3.6 × 10–4 as described by others14. We used the marginal
likelihood estimates from the triplicate BEAST runs as input to Path Sampling and
Stepping Stone Sampling analyses75,76 and determined that the Strict Constant
model was optimal for this dataset. To further conﬁrm the temporal signal in our
tree, we used the TIPDATINGBEAST package77 in R78 to resample tip-dates from
our alignment, generating 20 new datasets with randomly assigned dates—BEAST
analysis using the same Strict Clock prior conditions found no evidence of
temporal signal in these replicates, indicating that the signal in our tree was not
found by chance (Supplementary Figure 5).
Macrolide resistant SNPs were initially inferred using ARIBA39, which performs
localised assembly and mapping in comparison with a custom reference database
containing 23S sequences from Nichols (NR_076156.1) and SS14 reference strains
(NR_076531.1). Detailed inspection of ARIBA results revealed inconsistencies relating
to both contamination of publicly available datasets with other species and low
coverage. We therefore repeated the analysis using a stringent competitive mapping
approach43. Reads were simultaneously mapped to a region spanning 16S, 23S and 5S
from both the TPA Nichols genome and the most common contaminant in the public
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datasets (Streptococcus disgalactiae; NC_019042.1). Reads with anomalous mapping,
mapQ < 30, or for which only one of a read pair mapped were discarded, and TPA
variants were called with bcftools v1.2, requiring a minimum of two supporting reads
per strand, ﬁve in total to support a variant, and twelve at each position, as well as
requiring alleles not pass a Chi Square test (p < 0.01) for the presence of strand bias,
map quality bias, base quality bias and tail bias (available from bcftools in the PV4
option) using code available at https://github.com/matbeale/
Global_Syphilis_Phylo_2019. Sites not meeting these criteria, or those showing a
mixed allele proﬁle (10–90% of reads) were marked as uncertain in all analyses.
Non-synonymous penicillin binding protein gene variants in pbp1
(TPANIC_0500), pbp2 (TPANIC_0760), mrcA (TPANIC_0705) and Tp47
(TPANIC_0574) were inferred using the same stringent mapping approach
described above, using gene sequence references corresponding to the nucleotide
sequences from the Nichols genome (NC_021490.2). Functional inference of
amino acid changes was performed by inputting the gene amino acid sequences
into the SIFT47 server (available at http://sift.bii.a-star.edu.sg). The treponema-
speciﬁc Tp47 protein (TPANIC_0574) did not return a result from SIFT due to
insufﬁcient sequences being found during the PSIBLAST step.
Processing of data, and all statistical analysis was performed in R78 v3.4.1,
primarily using the phytools and ape packages. Phylogenies were plotted using
ggtree79, and ﬁgures were produced using ggplot280.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Raw sequencing reads for all novel sequences were deposited at the European Nucleotide
Archive (ENA) under project PRJEB20795. All accessions (both novel and previously
published) used in this project are listed in Supplementary Data 1, along with all
metadata used for analysis in Figs. 1, 2 and 3, and Supplementary Figures 1, 2, 3, 4 and 5.
The maximum likelihood phylogeny and metadata from this study are also available for
interactive exploration in a Microreact project [https://microreact.org] at https://
microreact.org/project/rJ6mBc-rm/9c1fdf1c.
Code availability
All code and source ﬁles for downstream analysis are available at https://doi.org/10.6084/
m9.ﬁgshare.7688093.
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